TAHAN, F. Et Al. 2008. Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappa B p65-associated histone acetyltransferase activity. CLINICAL AND EXPERIMENTAL ALLERGY , vol.38, no.5 , 805-811.

TAHAN, F., Jazrawi, E., Moodley, T., Rovati, G. E. , & Adcock, I. M. , (2008). Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappa B p65-associated histone acetyltransferase activity. CLINICAL AND EXPERIMENTAL ALLERGY , vol.38, no.5, 805-811.

TAHAN, FULYA Et Al. "Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappa B p65-associated histone acetyltransferase activity," CLINICAL AND EXPERIMENTAL ALLERGY , vol.38, no.5, 805-811, 2008

TAHAN, FULYA Et Al. "Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappa B p65-associated histone acetyltransferase activity." CLINICAL AND EXPERIMENTAL ALLERGY , vol.38, no.5, pp.805-811, 2008

TAHAN, F. Et Al. (2008) . "Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappa B p65-associated histone acetyltransferase activity." CLINICAL AND EXPERIMENTAL ALLERGY , vol.38, no.5, pp.805-811.

@article{article, author={FULYA TAHAN Et Al. }, title={Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappa B p65-associated histone acetyltransferase activity}, journal={CLINICAL AND EXPERIMENTAL ALLERGY}, year=2008, pages={805-811} }